Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis B immunoglobulins to induce HBsAg clearance in chronic hepatitis B
2021-005362-18Phase 2Active
- Sponsor
- Hannover Medical School
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of hepatitis B immune globulin in Chronic Hepatitis B (CHB) (2 cohorts), sponsored by Hannover Medical School. Primary endpoint: Primary efficacy endpoint. Started Nov 2021; status: active.
02
Drugs
hepatitis B immune globulin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2021-005362-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005362-18.